Filing Flows

Filing Flows › Companies › Integrated Biopharma › Cash flow

Integrated Biopharma cash flow, quarter by quarter

Latest: Q4 FY26 · from the cash-flow statements filed with the SEC

Free cash flow−$1.3M in Q4 FY26

Operating cash flow−$1.2M
Capital spending−$149K
Free cash flow−$1.3M
Cash conversion cycle84 days

Analysis

In Q4 FY26, Integrated Biopharma generated −$1.2M of operating cash flow and spent $149K on capital projects, leaving free cash flow of −$1.3M. That is $1.9M less than in Q4 FY25 ($601K).

Operating cash flow was −$1.2M against net income of −$1.4M. The largest differences: inventory −$1.0M, deferred taxes +$512K, receivables +$321K.

Its cash conversion cycle was 84 days (receivables 32 + inventory 80 − payables 29).

Free cash flow

Integrated Biopharma: free cash flow by quarterIntegrated Biopharma: free cash flow by quarter$601KQ1 FY25$172KQ2 FY25$500KQ3 FY25$601KQ4 FY25$1.1MQ1 FY26$593KQ2 FY26$517KQ3 FY26−$1.3MQ4 FY26
Operating cash flow less capital spending.
Integrated Biopharma: operating cash flow against capital spendingIntegrated Biopharma: operating cash flow against capital spendingOperating cash flowCapital spending$657K$56KQ1 FY25$201K$29KQ2 FY25$616K$116KQ3 FY25$591K−$10KQ4 FY25$1.3M$173KQ1 FY26$617K$24KQ2 FY26$517K$0Q3 FY26−$1.2M$149KQ4 FY26
Latest (Q4 FY26): Operating cash flow −$1.2M, Capital spending $149K.

Capital allocation, year by year

Integrated Biopharma: where the cash came from (up) and went (down), by fiscal yearIntegrated Biopharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY22: Operating cash flow $4.1MFY22: Net borrowing −$3.5MFY22: Shares issued $34KFY22: Asset sales $21KFY22: Capital spending −$486K$4.1MFY22FY23: Operating cash flow $1.2MFY23: Net borrowing −$136KFY23: Asset sales $1KFY23: Capital spending −$116K$1.2MFY23FY24: Operating cash flow $943KFY24: Net borrowing −$42KFY24: Shares issued $13KFY24: Capital spending −$553K$956KFY24FY25: Operating cash flow $2.1MFY25: Net borrowing −$8KFY25: Shares issued $86KFY25: Capital spending −$191K$2.2MFY25FY26: Operating cash flow $1.2MFY26: Net borrowing −$45KFY26: Asset sales $6KFY26: Capital spending −$346K$1.2MFY26
Over these 5 years operating cash flow totalled $9.6M; the largest uses were net borrowing ($3.8M) and capital spending ($1.7M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$4.5M
Debtnone
Net cash$4.5M

Integrated Biopharma funds itself: free cash flow was — over the last twelve months, with $4.5M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Integrated Biopharma: sources (+) and uses (−) of cash, Q4 FY26Integrated Biopharma: sources (+) and uses (−) of cash, Q4 FY26Cash drawn (+) / kept (−)$1.4MOperating cash flow−$1.2MCapital spending−$149KNet borrowing (+) / repaid (−)−$12K

From profit to cash

Integrated Biopharma: net income to operating cash flow, Q4 FY26Integrated Biopharma: net income to operating cash flow, Q4 FY26Net income−$1.4MDepreciation & amortization$70KStock-based pay$51KDeferred taxes$512KImpairments$30KReceivables$321KInventory−$1.0MPayables$227KAccrued liabilities$17KOperating cash flow−$1.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q4 FY2632802984
Q3 FY2632712282
Q2 FY2631772088
Q1 FY2634782092
Q4 FY2534701786
Q3 FY2530771988
Q2 FY2531902299
Q1 FY2531842095

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q4 FY26−$1.2M−$149K−$12K—$1.4M−$1.3M
Q3 FY26$517K—−$11K—−$512K$517K
Q2 FY26$617K−$24K−$11K—−$582K$593K
Q1 FY26$1.3M−$173K−$11K—−$1.1M$1.1M
Q4 FY25$591K$10K−$1K$68K−$654K$601K
Q3 FY25$616K−$116K——−$500K$500K
Q2 FY25$201K−$29K—$18K−$190K$172K
Q1 FY25$657K−$56K−$7K—−$594K$601K

Integrated Biopharma: income statement and cash flow

Integrated Biopharma, Q4 FY26: revenue $9.8M (-31% year over year), operating margin -8.9%. The chart follows the revenue to costs, profit and cash.

Integrated Biopharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.